News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
Researchers used a genome-scale CRISPRi platform to identify genetic interactions with an inhibitor for a mutant form of KRAS in models of lung and pancreatic cancer.
The researchers created a resource of cancer dependencies and developed a framework to prioritize existing cancer drug targets and suggest new ones.
A team led by Walter and Eliza Hall Institute researchers found that ovarian tumors with complete BRCA1 methylation and silencing were more susceptible to treatment.
The researchers said their findings could help classify BRCA1 variants, particularly one whose impact on cancer risk is currently not clear.